During Thursday’s current trade, Canadian National Railway (USA) (NYSE:CNI)’s shares incline 1.69% to $61.46.
CN (CNR.TO) (CNI) signed a memorandum of understanding (MOU) with the Port of New Orleans that will see the parties develop greater supply chain efficiencies aimed at drawing more container traffic over the port to North American markets.
The Port of New Orleans has an intermodal rail terminal adjacent to its Napoleon Avenue Container Terminal providing on-dock access for all rail shipments. The new Mississippi River Intermodal Terminal is now under construction. The US$25-million project, when accomplished in the first quarter of 2016, will result in a modern, efficient intermodal container transfer terminal located within the container yard, offering on-dock access and improving CN’s link to the terminal and assisting grow its container volumes.
The New Orleans Public Belt Railroad (NOPBR), a switching railroad with the primary mission of serving the Port of New Orleans and local industries, also signed the CN-Port of New Orleans MOU.
Canadian National Railway Company, together with its auxiliaries, engages in rail and related transportation business in North America. It offers transportation services that comprise rail, intermodal container, and trucking services; and supply chain solutions, counting warehousing and distribution, cargoflo, logistics parks, freight forwarding, customs brokerage service, industrial development, and marine services.
Kimco Realty Corp (NYSE:KIM)‘s shares gain 1.14% to $23.89, during the current trading session Thursday’s, hitting its highest level.
Kimco Realty Corp. (KIM) will declare its second quarter earnings on Tuesday, July 28, 2015 after market close. You are invited to listen to our quarterly earnings conference call, which will be broadcast live over the Internet on Wednesday, July 29, 2015 at 10:00 AM EDT.
Kimco Realty Corporation is an independent real estate investment trust. The firm invests in the real estate markets across North America. It is primarily engaged in acquisitions, development, and administration of neighborhood and community shopping centers.
In a mid-morning trade, Galena Biopharma Inc (NASDAQ:GALE)‘s shares surge 1.07% to $1.89.
Galena Biopharma, Inc. (GALE) declared that data from the Company’s Phase 2 clinical trial of GALE-401 was presented at the European Hematology Association 20th Congress in Vienna, Austria. The GALE-401 Phase 2 pilot study is a single arm, open label, multi-center study evaluating the efficacy and safety of anagrelide controlled release in subjects with thrombocytosis secondary to essential thrombocythemia (ET) and other myeloproliferative neoplasms (MPNs).
he poster presentation, entitled, “Phase 2 Study of a Novel Controlled-Release Formulation of Anagrelide (GALE-401) in Subjects with Myeloproliferative Neoplasm (MPN)-Related Thrombocytosis,” was presented on Saturday, June 13, 2015. The Phase 2 study demonstrated that GALE-401 was well tolerated with primarily Grade 1 and 2 toxicities in 16 of the 18 subjects enrolled. The efficacy shown in the trial compares favorably to historical anagrelide immediate release (IR) response rates with the following platelet response: overall response rate (ORR) of 78% (14/18); complete response (CR) of 39% (7/18); partial response (PR) of 39% (7/18). The median time to response was 5 weeks (range, 3-10), and the median duration of response has not yet been reached. Based on the data, the investigators concluded that GALE-401 remains a viable potential treatment option for MPNs, and a randomized trial comparing GALE-401 as compared to anagrelide IR is warranted. Final data from the GALE-401 Phase 2 trial is predictable to be presented at the American Society of Hematology conference in December.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care. Its commercial products comprise Abstral, a sublingual tablet that is used for the administration of breakthrough pain in patients with cancer; and Zuplenz, an oral soluble film for use in the prevention of emetogenic chemotherapy-induced, radiotherapy-induced, and post-operative nausea and vomiting.
Umpqua Holdings Corp (NASDAQ:UMPQ), during its Thursday’s current trading session 0.16% gain and closed at $18.39.
Umpqua Holdings Corporation (UMPQ), the parent company of Umpqua Bank and Umpqua Investments, Inc., declared that its Board of Directors has approved a quarterly cash dividend in the amount of $0.15 per common share. The dividend is payable on July 15, 2015, to shareholders of record as of June 30, 2015.
Umpqua Holdings Corporation, through its auxiliaries, engages in the commercial and retail banking, and retail brokerage businesses. It operates through two segments, Community Banking and Home Lending. The Community Banking segment provides loan and deposit products to business and retail customers. The Home Lending segment originates, sells, and services residential mortgage loans. It also offers various deposit products, such as non-interest bearing checking accounts, interest bearing checking and savings accounts, money market accounts, and certificates of deposit; financial planning, trust, and investments services to high net worth individuals; and retail brokerage and investment advisory services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
